Display Single Record

FOI Request

Disclosure ID

FOI/02390

Request Date

April 25, 2018

Subject

Drug Stock

Description

1. Has your trust accepted or is it currently accepting manufacturer provision of free of charge drug stock between licensing and NICE funding?

2. Has your trust accepted or is it currently accepting the following list of drugs in psoriasis:

   1. Brodalumab [Kyntheum]
      

   2. Guselkumab [Tremfya]        

   3. Ixekizumab [Taltz]          

   4. Secukinumab [Cosentyx]         

3. Has your trust accepted or is it currently accepting the following list of drugs in Rheumatoid Arthritis:

   1. Tofacitinib [Xeljanz]

   2. Baricitinib [Olumiant]  

   3. Golimumab [Simponi]   

   4. Certolizumab [Cimzia]   

   5. Apremilast [Otezla]   

   6. Tocilizumab [Ro Actemra]     

4. Has your trust accepted or is it currently accepting the following list of drugs in Ankylosing Spondylitis or Psoriatic Arthritis:

   1. Secukinumab [Cosentyx]     

5. Has your trust accepted or is it currently accepting the following list of drugs in Ulcerative Colitis:

   1. Golimumab [Simponi]    

6. If your trust has not accepted manufacturer provision of free of charge drug stock, what have been the reasons for this? [……………………………..]

7. In future, will your trust be able to accept manufacturer provision of free of charge drug stock?

8. What is the preferred distribution channel for the provision of free of charge drug stock?

   1. Homecare     

   2. Delivered directly to hospital/Trust    

   3. Other (please provide details)       

9. For how long is free of charge drug stock typically provided for each patient ?

   first dose  

   first month 

   first 3 months   

   Other   [………………………………..]

Response

1. Yes
2. :-
   1. No
   2. No
   3. No
   4. Yes
3. :-
   1. No
   2. No
   3. No
   4. No
   5. No
   6. No
4. :-
   1. No
5. :-
   1. No
6. Each request made on case by case request to Drugs and Therapeutics committee
7. Only on case by case approval by Drugs and Therapeutics committee
8. :-
   1. Yes
   2. Yes
   3. Depends on Pharma Funded schemes
9. Depends on drug and clinical need as agreed by D&T committee

Attachment 1

Attachment 2

Attachment 3

Attachment 4

Attachment 5

Attachment 6

Attachment 7

Attachment 8

Attachment 9